Sutro Biopharma

Sutro Biopharma:
Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA & ASH 2019 – additional NHL cohort data will be presented at ASH 2020 and a dose expansion of Ph 1 expected to begin enrolling 1H21. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated it’s clinically efficacious at multiple doses (starting at 2.9 mg/kg). Additional Phase 1 data expected during a KOL in 4Q20 and dose-expansion of Ph 1 trial is expected to begin enrolling in 4Q20.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States
Suite 150
South San Francisco, CA 94080
United States
More info:
My account:
Company Participants at Sutro Biopharma STRO-002 Data Virtual KOL Event 2020
- Annie Chang
- Arturo Molina, MD, MS, FACP, Chief Medical Officer
- Bill Newell, Chief Executive Officer
- Edward Albini, Chief Financial Officer
- Trevor Hallam, Ph.D., Chief Scientific Officer
Top 10 Holders of Sutro Biopharma, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Eventide Asset Management LLC | 10.21 | 2,370,975 | 47.23 | Stakes | 12/31/20 |
BVF Partners LP | 5.20 | 2,368,392 | 47.18 | Stakes | 5/22/20 |
Franklin Advisers, Inc. | 9.52 | 2,211,423 | 44.05 | 13F | 12/31/20 |
RA Capital Management LP | 9.12 | 2,118,212 | 42.19 | 13F | 12/31/20 |
Vanguard Group, Inc. (Subfiler) | 8.02 | 1,863,040 | 37.11 | 13F | 12/31/20 |
BVF, Inc. | 7.98 | 1,854,162 | 36.93 | 13F | 12/31/20 |
SV Health Investors LLC | 7.86 | 1,824,542 | 36.34 | 13F | 12/31/20 |
The Vanguard Group, Inc. | 7.51 | 1,743,397 | 34.73 | Funds | 2/28/21 |
Baillie Gifford & Co. | 7.30 | 1,695,654 | 33.78 | 13F | 12/31/20 |
Samsara Biocapital LLC | 7.21 | 1,675,579 | 33.38 | 13F | 12/31/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.